PDCD1 and renal cell carcinoma: Studies have shown that the more effective tumor‐specific antigens are formed, the better the efficacy of PD‐1/PD‐L1 blockers is, and it is related to the clinical PFS (progression‐free survival) of patients, such as highly immunogenic melanoma, renal cell carcinoma, and non‐small cell lung cancer.